Highlights IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 18/05/2026 BST			5-day change	1st Jan Change
1.268 ^SEK	+1.60%		+0.79%	-35.63%

05-06	IRLAB Q1 operating result swings to profit of SEK 10.7 mln	RE
05-06	Irlab reports growth in revenue and operating profit	FW

Highlights

05-06	IRLAB Q1 operating result swings to profit of SEK 10.7 mln	RE
05-06	IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02-26	IRLAB Therapeutics AB Secures Milestone Payment for First Patient Dosed in Phase Ib Study with IRL757 in Parkinson's Disease	CI
02-25	IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-20	Irlab Therapeutics Receives Scientific Advisory Board Confirmation on Next Steps for Pirepemat	CI
01-19	IRLAB Therapeutics AB Enters Collaboration Agreement with Biomia ApS Applying Integrative Screening Process	CI
12-23	Irlab Therapeutics gets approvals for phase Ib study of IRL757	RE
12-23	IRLAB Therapeutics AB Receives Approval for a Phase Ib Study with IRL757 in Parkinson's Disease	CI
12-11	The European Patent Office Intends to Grant a New Patent for Mesdopetam to IRLAB Therapeutics AB	CI
29/10/25	IRLAB Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
04/09/25	IRLAB Therapeutics AB Receives an Additional 'Composition of Matter Patent' in China	CI
27/08/25	IRLAB Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
28/05/25	IRLAB Reports Positive Results from the Second Part of A Phase I Study with IRL757	CI
13/05/25	Irlab Therapeutics Obtains US Patent for Parkinson's Disease Drug Ingredient	MT
13/05/25	IRLAB Therapeutics AB Receives Patent Expanding the Patent Protection for the Drug Candidate Mesdopetam in the US	CI
07/05/25	Irlab Therapeutics Q1 Net Sales SEK 4.4 Mln	RE
07/05/25	IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
01/04/25	IRLAB Therapeutics AB to Present Clinical and Preclinical Data at the AD/PD?? 2025: 19th International Conference on Alzheimer's & Parkinson's Diseases	CI
28/03/25	IRLAB Provides Additional Efficacy Data from the Phase IIb Study of Pirepemat in Patients with Parkinson's Disease	CI
27/03/25	IRLAB Therapeutics AB to Initiate A Study of Irl757 in Parkinsons's Disease with Full Financial Backing from Its Development Partner Msrd	CI
05/03/25	IRLAB Reports Topline Results from a Phase IIb Study of Pirepemat in Patients with Parkinson's Disease	CI
27/02/25	IRLAB Therapeutics AB Publishes Phase IIb Data on Mesdopetam in Movement Disorders Clinical Practice	CI
20/02/25	IRLAB Gets Positive Feedback On Phase III Program For Mesdopetam From EMA	RE
20/02/25	IRLAB Therapeutics AB Receives Positive Feedback from Ema Confirming Alignment with FDA on Phase III Program for Mesdopetam	CI
12/02/25	IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI